Style | Citing Format |
---|---|
MLA | Zarifyeganeh M, et al.. "Crispr/Cas9 Ret Gene Knockout in Medullary Thyroid Carcinoma Cell-Lines: Optimization and Validation." Iranian Journal of Public Health, vol. 51, no. 5, 2022, pp. 1084-1096. |
APA | Zarifyeganeh M, Farhud DD, Rahimpour A, Sheikholeslami S, Shivaei S, Hedayati M (2022). Crispr/Cas9 Ret Gene Knockout in Medullary Thyroid Carcinoma Cell-Lines: Optimization and Validation. Iranian Journal of Public Health, 51(5), 1084-1096. |
Chicago | Zarifyeganeh M, Farhud DD, Rahimpour A, Sheikholeslami S, Shivaei S, Hedayati M. "Crispr/Cas9 Ret Gene Knockout in Medullary Thyroid Carcinoma Cell-Lines: Optimization and Validation." Iranian Journal of Public Health 51, no. 5 (2022): 1084-1096. |
Harvard | Zarifyeganeh M et al. (2022) 'Crispr/Cas9 Ret Gene Knockout in Medullary Thyroid Carcinoma Cell-Lines: Optimization and Validation', Iranian Journal of Public Health, 51(5), pp. 1084-1096. |
Vancouver | Zarifyeganeh M, Farhud DD, Rahimpour A, Sheikholeslami S, Shivaei S, Hedayati M. Crispr/Cas9 Ret Gene Knockout in Medullary Thyroid Carcinoma Cell-Lines: Optimization and Validation. Iranian Journal of Public Health. 2022;51(5):1084-1096. |
BibTex | @article{ author = {Zarifyeganeh M and Farhud DD and Rahimpour A and Sheikholeslami S and Shivaei S and Hedayati M}, title = {Crispr/Cas9 Ret Gene Knockout in Medullary Thyroid Carcinoma Cell-Lines: Optimization and Validation}, journal = {Iranian Journal of Public Health}, volume = {51}, number = {5}, pages = {1084-1096}, year = {2022} } |
RIS | TY - JOUR AU - Zarifyeganeh M AU - Farhud DD AU - Rahimpour A AU - Sheikholeslami S AU - Shivaei S AU - Hedayati M TI - Crispr/Cas9 Ret Gene Knockout in Medullary Thyroid Carcinoma Cell-Lines: Optimization and Validation JO - Iranian Journal of Public Health VL - 51 IS - 5 SP - 1084 EP - 1096 PY - 2022 ER - |